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Abstract
Background: Gene expression profiling has shown its ability to identify with high accuracy low cytogenetic risk
acute myeloid leukemia such as acute promyelocytic leukemia and leukemias with t(8;21) or inv(16). The aim of
this gene expression profiling study was to evaluate to what extent suboptimal samples with low leukemic blast
load (range, 2-59%) and/or poor quality control criteria could also be correctly identified.
Methods: Specific signatures were first defined so that all 71 acute promyelocytic leukemia, leukemia with t(8;21)
or inv(16)-AML as well as cytogenetically normal acute myeloid leukemia samples with at least 60% blasts and
good quality control criteria were correctly classified (training set). The classifiers were then evaluated for their
ability to assign to the expected class 111 samples considered as suboptimal because of a low leukemic blast load
(n = 101) and/or poor quality control criteria (n = 10) (test set).
Results: With 10-marker classifiers, all training set samples as well as 97 of the 101 test samples with a low blast
load, and all 10 samples with poor quality control criteria were correctly classified. Regarding test set samples, the
overall error rate of the class prediction was below 4 percent, even though the leukemic blast load was as low as
2%. Sensitivity, specificity, negative and positive predictive values of the class assignments ranged from 91% to
100%. Of note, for acute promyelocytic leukemia and leukemias with t(8;21) or inv(16), the confidence level of the
class assignment was influenced by the leukemic blast load.
Conclusion: Gene expression profiling and a supervised method requiring 10-marker classifiers enable the
identification of favorable cytogenetic risk acute myeloid leukemia even when samples contain low leukemic blast
loads or display poor quality control criterion.
Background
Prognostic evaluation is a critical step in newly diag-
nosed patients with acute myeloid leukemia (AML) in
order to identify those at high risk of relapse. For AML
patients, cytogenetic abnormalities as well as gene muta-
tions and/or hyper-expressions detected at diagnosis are
the main prognostic factors guiding the initial treatment
strategy in a risk-oriented manner [1-4]. Hypergranular
acute promyelocytic leukemia (APL), as well as AMLs
with either translocation t(8;21)(q22;q22) [t(8;21)-AMLs]
or inversion inv(16)(p13q22)/t(16;16)(p13;q22) [inv(16)-
AMLs], are well-defined entities associated with a favor-
able outcome [1,3]. They can be distinguished from all
other AML subtypes based on specific chromosomal
alterations and fusion genes: PML/RAR-alpha fusion
gene with reciprocal translocation t(15;17)(q24;q21) for
APLs, AML1/ETO (also called RUNX1/RUNX1T1)
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gene for AMLs with either inv(16)(q21;q22) or balanced
reciprocal translocation t(16;16)(q21;q22). Of note, in up
to 15 percent of APLs, no translocation t(15;17)(q24;
q21) is detected by conventional cytogenetics at diagno-
sis, despite PML/RARA fusion gene is detected using
molecular assays [5,6]. Similarly, cryptic t(8;21)(q22;q22)
and inv(16)(q21;q22), undetected by conventional cyto-
genetics, have also been reported [7-9].
With samples containing a high leukemic blast load,
microarray-based gene expression profiling (GEP) and
class prediction analyses have demonstrated their ability
to assign AML samples to one of these three well char-
acterized favorable cytogenetic risk AML subtypes, with
high accuracy and low error rates [10-18]. One of the
largest class prediction analyses in AML achieved 100
percent classification accuracy with respect to APL, t
(8;21)-AML, and inv(16)-AML subtypes, indeed [10].
However, in the majority of those studies, the minimum
percentage of leukemic cells within each sample is most
often above 60 percent [10-18], an arbitrary threshold
that is significantly different from the one used by cytol-
ogists for the diagnosis of AML, i.e., excess of blasts
greater or equal to 20 percent.
To our knowledge, the impact of the leukemic blast
load and/or of the sample quality on microarray-derived
class prediction results has not been specifically studied
in AMLs. For centers wishing to integrate microarray-
based GEP in a routine prognostic workflow for newly
diagnosed AML patients, one critical issue is the ability
to perform accurate class prediction analysis with sub-
optimal samples, i.e., containing as low as 20 percent
blasts and even below, and/or not fulfilling all quality
control criteria along their process.
In this study, GEP was first used to define a limited
set of markers allowing to correctly classify 71 patients
with either APL, t(8;21)-AML, inv(16)-AML or cytogen-
etically normal AML (NK-AML) based on samples con-
taining at least 60 percent of leukemic blasts and
characterized by good quality control criteria (training
set including optimal samples). The classifiers derived
from this first supervised analysis were then evaluated
for their ability to assign to the correct class 111 subop-
timal samples with low leukemic blast load (from 2 to
59 percent) and/or poor quality control criteria (test set
including suboptimal samples), as well as duplicates of
three AML cell lines.
Methods
Characteristics of the patients and samples
A total of 182 bone marrow or peripheral blood samples
from 97 AML patients, diagnosed with either APL (n =
18), t(8;21)-AML (n = 19), inv(16)-AML (n = 29), or
NK-AML (n = 31), followed at Angers University
Hospital (n = 72) or Reims University Hospital (n = 25),
were analyzed, as well as duplicated samples of NB4,
Kasumi-1, and ME-1 cell lines (n = 6 samples), which
are derived from patients with APL, t(8;21)-AML and
inv(16)-AML, respectively. In addition, 18 samples of
unique (n = 9) or pooled (n = 9) normal bone marrows
obtained from 12 healthy volunteers were included in
the study. The main characteristics of AML patients and
samples are summarized in Tables 1 and 2. Conven-
tional cytogenetic banding, fluorescence in situ hybridi-
zation, and RT-PCR analysis of fusion gene transcripts
were used to identify patients with APL, t(8;21)-AML or
inv(16)-AML, as previously reported [19]. Analysis of
NPM1, FLT3 and CEBPA for mutations was also per-
formed for all patients [20-23]. All participants gave
their written informed consent, and the study was
approved by the Ethical Committee of Angers University
Hospital.
The gene expression dataset, generated from 206 sam-
ples (182 AML samples, duplicated samples of NB4,
Kasumi-1, and ME-1 cell lines, 18 samples of unique or
combined normal bone marrows), was divided into a
Training Set (n = 89 samples) and a Test Set (n = 117
Table 1 Characteristics of the patients.
Covariates Overall APLs t(8;21)-
AMLs
inv(16)-
AMLs
NK-AMLs
Patients N = 97 N = 18 N = 19 N = 29 N = 31
Gender
Males 44 7 13 15 9
Females 53 11 6 14 22
Age at diagnosis
Median (years) 54 56 53 38 60
Range 18-87 19-87 18-84 18-70 25-78
Leukocytosis at
diagnosis
WBC ≥ 30 G/L 39 2 6 12 19
FAB classification
M1 or M2 45 0 18 6 21
M3 18 18 0 0 0
M4 or M5 34 0 0 24 10
Cytogenetics
Expected
anomaly*
62 16 19 27 0
Normal karyotype 34 2 0 1 31
Karyotype failure 1 0 0 1 0
Gene mutations
FLT3-ITD
$ 19 2 1 2 14
FLT3-D835
& 72 2 2 1
NPM1 18 0 0 1 17
CEBPA (mono-
allelic)
40 2 1 1
WBC, white blood cells. * t(15;17), t(8;21), inv(16) or t(16;16) for APL, t(8;21)-
AML and inv(16)-AML, respectively detected.
$ Internal tandem duplication.
&Mutation Asp835 of the tyrosine kinase domain.
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class markers (classifiers), included 18 samples of unique
or pooled normal bone marrows (see details about the
pools below) as well as 71 AML samples obtained from
patients (bone marrow samples, n = 48; peripheral
blood samples, n = 23) newly diagnosed with APL (n =
14 patients), t(8;21)-AML (n = 14 patients), inv(16)-
AML (n = 15 patients) or NK-AML (n = 28 patients),
which contained at least 60 percent blasts. The class
prediction analysis was performed on a Test Set includ-
ing 111 suboptimal AML samples (bone marrow sam-
ples, n = 78; peripheral blood samples, n = 33 obtained
from 53 patients), i.e., with a low leukemic blast load (n
= 101 samples containing from 2 to 56 percent blasts)
and/or poor quality control criteria (n = 10 samples) as
well as duplicated samples of NB4, Kasumi-1, and ME-1
cell lines (n = 6 samples). Among test samples with
optimal quality control criteria, 22 originally contained
less than 60% blasts (range, 5-56 percent blasts),
whereas 79 were high blast load ones artificially diluted
within one of the five pools of normal bone marrows
(see details below and Tables 2 and 3). The 10 samples
with suboptimal quality control criteria were character-
ized by either a low RNA integrity number suggestive of
RNA degradation (n = 2), a low cRNA amount obtained
after total RNA amplification and labeling (cRNA hybri-
dized on BeadChips < 750 micrograms) (n = 7) or both
(n = 1) (Tables 2 and 3).
Sample preparation for gene expression profiling
Blasts and mononuclear cells were purified by Ficoll-
Hypaque density gradient centrifugation from bone mar-
row or peripheral blood samples (Nygaard, Oslo, Norway).
Isolated cell samples were then immediately cryopre-
served. Total RNAs were extracted from 10
7 thawed cells
using RNEasy
® Mini Kits (Qiagen Incorporation, Valencia,
USA). Total RNA quantification was performed using the
Nanodrop ND-1000 spectrophotometer (Thermo Fisher
Scientific Incorporation, Waltham, USA) according to
manufacturer recommendations. Integrity of the extracted
RNAs was assessed with the Bioanalyzer 2100 and the
RNA6000 Nano kit (Agilent Technologies Incorporation,
Santa Clara, USA). A RNA integrity number (RIN) greater
or equal to 7.00 was achieved for 203 samples (RNA
degradation observed for 3 AML samples). No sign of
DNA contamination was detected in any of the 206 sam-
ples analyzed. The starting amount of total RNA used for
the reactions was 200 nanograms per sample, for all sam-
ples. The Illumina Total Prep RNA Amplification Kit
(Applied Biosystems/Ambion, Austin, USA) was used to
generate biotinylated, amplified cRNA according to the
manufacturer recommendations (see additional file 1 for
details). To study the leukemic blast load effect on the
class prediction accuracy, besides including 22 samples
with good quality control criteria that originally contained
less than 60 percent of leukemic blasts, 79 artificially gen-
erated low leukemic blast load samples, via a “dilution/
mixture” approach, were also assessed (see additional file 1
for details for the generation of low leukemic blast load
AML samples by a “dilution/mixture” approach). Hybridi-
zation on Illumina HumanHT-12 v3 Expression Bead-
Chips, staining and detection of cRNAs on microarrays
using an I-Scan system were performed according to Illu-
mina’s protocol (see additional file 1 for details).
Data analyses
GenomeStudio 2010.3 software (Illumina Inc., San
Diego, USA) and its Gene Expression Analysis Module
Table 2 Characteristics of the samples.
Covariates Overall APLs t(8;21)-
AMLs
inv(16)-
AMLs
NK-
AMLs
Samples* N = 206 N = 40 N = 39 N = 52 N = 57
Groups
Training Set AML
samples
71 14 14 15 28
Training Set
NBM
&samples
18 ––––
Test Set AML
samples*
111 24 23 35 29
Test Set AML cell
lines
6222–
Samples with
optimal QCC
#
Blast % < 60%
(undiluted)
22 3 5 11 3
Diluted at 50% 28 5 5 5 13
Diluted at 75% 27 5 4 5 13
Diluted at 90% 12 4 4 4 0
Diluted at 95% 12 4 4 4 0
Overall, blasts
< 60%
101 21 22 29 29
Overall, blasts
≥ 40% < 60%
23 2 2 6 13
Overall, blasts
≥ 20% < 40%
40 6 9 10 15
Overall, blasts
≥ 10% < 20%
15 4 4 6 1
Overall, blasts
≥ 5% < 10%
14 5 4 5 0
Overall, blasts
<5 %
94320
Samples with poor
QCC
#
10 3 1 6 0
cRNA
$ < 750
ng
71150
Low RIN
% 22000
Low RIN + low
cRNA
10010
* including the three AML cell lines.
# quality control criteria.
$ labeled cRNA
to be hybridized on Illumina Beadchips.
% RNA integrity number lower than 7.00.
&NBM, normal bone marrow.
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UPN Cell Source Time Blasts % Dilution QCC Real Class Assigned Class Confidence
NB4 BM Diagnosis 100 No Dilution OK APLs Test Set APLs 10.802
NB4 BM Diagnosis 100 No Dilution OK APLs Test Set APLs 17.507
UPN53 BM Diagnosis 43 Dilution 50% OK APLs Test Set APLs 26.028
UPN22 BM Diagnosis 40 Dilution 50% OK APLs Test Set APLs 29.91
UPN65 BM Diagnosis 39 Dilution 50% OK APLs Test Set APLs 26.403
UPN40 BM Diagnosis 33 Dilution 50% OK APLs Test Set APLs 29.91
UPN50 PB Diagnosis 27 Dilution 50% OK APLs Test Set APLs 19.2
UPN53 BM Diagnosis 22 Dilution 75% OK APLs Test Set APLs 20.904
UPN22 BM Diagnosis 20 Dilution 75% OK APLs Test Set APLs 29.91
UPN65 BM Diagnosis 20 Dilution 75% OK APLs Test Set APLs 15.763
UPN40 BM Diagnosis 16 Dilution 75% OK APLs Test Set APLs 26.425
UPN5 PB Diagnosis 15 No Dilution OK APLs Test Set APLs 17.193
UPN50 PB Diagnosis 14 Dilution 75% OK APLs Test Set APLs 10.46
UPN48 PB Diagnosis 11 No Dilution OK APLs Test Set APLs 23.005
UPN53 BM Diagnosis 9 Dilution 90% OK APLs Test Set APLs 16.749
UPN22 BM Diagnosis 8 Dilution 90% OK APLs Test Set APLs 15.781
UPN40 BM Diagnosis 7 Dilution 90% OK APLs Test Set APLs 10.143
UPN86 PB Diagnosis 7 No Dilution OK APLs Test Set APLs 11.641
UPN50 PB Diagnosis 6 Dilution 90% OK APLs Test Set APLs 2.661
UPN22 BM Diagnosis 4 Dilution 95% OK APLs Test Set APLs 7.665
UPN53 BM Diagnosis 4 Dilution 95% OK APLs Test Set APLs 1.201
UPN40 BM Diagnosis 3 Dilution 95% OK APLs Test Set APLs 10.667
UPN50 PB Diagnosis 3 Dilution 95% OK APLs Test Set APLs 4.337
UPN59 PB Diagnosis 70 No Dilution Low RIN APLs Test Set APLs 26.497
UPN82 BM Diagnosis 64 No Dilution Low RIN APLs Test Set APLs 22.822
UPN13 BM Diagnosis 30 No Dilution Low cRNA APLs Test Set APLs 18.651
Kasumi-1 BM Diagnosis 100 No Dilution OK t(8;21)-AMLs Test Set t(8;21)-AMLs 5.184
Kasumi-1 BM Diagnosis 100 No Dilution OK t(8;21)-AMLs Test Set t(8;21)-AMLs 1.525
UPN30 PB Diagnosis 49 Dilution 50% OK t(8;21)-AMLs Test Set t(8;21)-AMLs 19.199
UPN69 PB Diagnosis 41 Dilution 50% OK t(8;21)-AMLs Test Set t(8;21)-AMLs 30.674
UPN51 BM Relapse 38 Dilution 50% OK t(8;21)-AMLs Test Set t(8;21)-AMLs 20.609
UPN76 PB Diagnosis 31 No Dilution OK t(8;21)-AMLs Test Set t(8;21)-AMLs 32.067
UPN69 BM Diagnosis 30 Dilution 50% OK t(8;21)-AMLs Test Set t(8;21)-AMLs 25.183
UPN26 BM Diagnosis 27 No Dilution OK t(8;21)-AMLs Test Set t(8;21)-AMLs 14.89
UPN30 PB Diagnosis 25 Dilution 75% OK t(8;21)-AMLs Test Set t(8;21)-AMLs 17.719
UPN61 BM Diagnosis 24 Dilution 50% OK t(8;21)-AMLs Test Set t(8;21)-AMLs 30.674
UPN69 PB Diagnosis 21 Dilution 75% OK t(8;21)-AMLs Test Set t(8;21)-AMLs 27.738
UPN21 BM Diagnosis 21 No Dilution OK t(8;21)-AMLs Test Set t(8;21)-AMLs 24.116
UPN95 BM Diagnosis 20 No Dilution OK t(8;21)-AMLs Test Set t(8;21)-AMLs 30.674
UPN51 BM Relapse 19 Dilution 75% OK t(8;21)-AMLs Test Set t(8;21)-AMLs 10.519
UPN94 PB Diagnosis 16 No Dilution OK t(8;21)-AMLs Test Set t(8;21)-AMLs 28.631
UPN69 BM Diagnosis 15 Dilution 75% OK t(8;21)-AMLs Test Set t(8;21)-AMLs 22.744
UPN30 PB Diagnosis 10 Dilution 90% OK t(8;21)-AMLs Test Set t(8;21)-AMLs 16.958
UPN69 PB Diagnosis 6 Dilution 90% OK t(8;21)-AMLs Test Set t(8;21)-AMLs 13.468
UPN30 PB Diagnosis 5 Dilution 95% OK t(8;21)-AMLs Test Set t(8;21)-AMLs 13.581
UPN61 BM Diagnosis 5 Dilution 90% OK t(8;21)-AMLs Test Set t(8;21)-AMLs 28.443
UPN51 BM Diagnosis 4 Dilution 90% OK t(8;21)-AMLs Test Set t(8;21)-AMLs 3.096
UPN69 PB Diagnosis 3 Dilution 95% OK t(8;21)-AMLs Test Set t(8;21)-AMLs 12.875
UPN51 BM Diagnosis 2 Dilution 95% OK t(8;21)-AMLs Test Set t(8;21)-AMLs 4.6
UPN61 BM Diagnosis 2 Dilution 95% OK t(8;21)-AMLs Test Set t(8;21)-AMLs 19.237
UPN30 PB Diagnosis 25 No Dilution Low cRNA t(8;21)-AMLs Test Set t(8;21)-AMLs 15.256
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ME-1 BM Diagnosis 100 No Dilution OK inv(16)-AMLs Test set inv(16)-AMLs 15.836
ME-1 BM Diagnosis 100 No Dilution OK inv(16)-AMLs Test set inv(16)-AMLs 18.901
UPN52 BM Diagnosis 56 No Dilution OK inv(16)-AMLs Test set inv(16)-AMLs 26.467
UPN45 BM Diagnosis 50 Dilution 50% OK inv(16)-AMLs Test set inv(16)-AMLs 30.188
UPN31 BM Diagnosis 50 No Dilution OK inv(16)-AMLs Test set inv(16)-AMLs 29.511
UPN88 BM Diagnosis 46 No Dilution OK inv(16)-AMLs Test set inv(16)-AMLs 31.576
UPN47 BM Diagnosis 41 Dilution 50% OK inv(16)-AMLs Test set inv(16)-AMLs 30.517
UPN37 BM Diagnosis 40 No Dilution OK inv(16)-AMLs Test set inv(16)-AMLs 28.551
UPN9 BM Diagnosis 35 No Dilution OK inv(16)-AMLs Test set inv(16)-AMLs 31.083
UPN87 PB Diagnosis 35 No Dilution OK inv(16)-AMLs Test set inv(16)-AMLs 29.511
UPN10 BM Diagnosis 33 Dilution 50% OK inv(16)-AMLs Test set inv(16)-AMLs 17.561
UPN43 PB Diagnosis 31 No Dilution OK inv(16)-AMLs Test set inv(16)-AMLs 24.289
UPN52 BM Diagnosis 28 Dilution 50% OK inv(16)-AMLs Test set inv(16)-AMLs 24.608
UPN45 BM Diagnosis 25 Dilution 75% OK inv(16)-AMLs Test set inv(16)-AMLs 23.687
UPN67 PB Diagnosis 24 No Dilution OK inv(16)-AMLs Test set inv(16)-AMLs 31.576
UPN36 PB Diagnosis 23 No Dilution OK inv(16)-AMLs Test set inv(16)-AMLs 27.432
UPN47 BM Diagnosis 20 Dilution 75% OK inv(16)-AMLs Test set inv(16)-AMLs 16.733
UPN37 BM Diagnosis 20 Dilution 50% OK inv(16)-AMLs Test set inv(16)-AMLs 26.644
UPN10 BM Diagnosis 16 Dilution 75% OK inv(16)-AMLs Test set inv(16)-AMLs 10.252
UPN52 BM Diagnosis 14 Dilution 75% OK inv(16)-AMLs Test set inv(16)-AMLs 6.543
UPN37 PB Relapse 14 No Dilution OK inv(16)-AMLs Test set t(8;21)-AMLs 4.33
UPN45 BM Diagnosis 10 Dilution 90% OK inv(16)-AMLs Test set inv(16)-AMLs 14.568
UPN47 BM Diagnosis 10 Dilution 90% OK inv(16)-AMLs Test set inv(16)-AMLs 15.298
UPN37 BM Diagnosis 10 Dilution 75% OK inv(16)-AMLs Test set inv(16)-AMLs 20.423
UPN10 BM Diagnosis 7 Dilution 90% OK inv(16)-AMLs Test set inv(16)-AMLs 8.479
UPN52 BM Diagnosis 6 Dilution 90% OK inv(16)-AMLs Test set APLs 0.6
UPN45 BM Diagnosis 5 Dilution 95% OK inv(16)-AMLs Test set inv(16)-AMLs 15.056
UPN47 BM Diagnosis 5 Dilution 95% OK inv(16)-AMLs Test set inv(16)-AMLs 2.293
UPN7 BM Relapse 5 No Dilution OK inv(16)-AMLs Test set t(8;21)-AMLs 0.473
UPN10 BM Diagnosis 4 Dilution 95% OK inv(16)-AMLs Test set inv(16)-AMLs 3.715
UPN52 BM Diagnosis 3 Dilution 95% OK inv(16)-AMLs Test set inv(16)-AMLs 3.79
UPN6 BM Diagnosis 74 No Dilution Low cRNA inv(16)-AMLs Test set inv(16)-AMLs 27.753
UPN45 BM Diagnosis 25 No Dilution Low cRNA inv(16)-AMLs Test set inv(16)-AMLs 31.005
UPN47 BM Diagnosis 20 No Dilution Low cRNA inv(16)-AMLs Test set inv(16)-AMLs 26.009
UPN79 BM Diagnosis 47 No Dilution Low cRNA inv(16)-AMLs Test set inv(16)-AMLs 29.75
UPN90 PB Diagnosis 9 No Dilution Low cRNA inv(16)-AMLs Test set inv(16)-AMLs 2.693
UPN23 BM Diagnosis 27 No Dilution Low RIN + Low cRNA inv(16)-AMLs Test set inv(16)-AMLs 24.111
UPN60 PB Diagnosis 50 No Dilution OK NK-AMLs Test Set inv(16)-AMLs 0.948
UPN72 BM Diagnosis 49 Dilution 50% OK NK-AMLs Test Set NK-AMLs 26.707
UPN8 BM Diagnosis 48 Dilution 50% OK NK-AMLs Test Set NK-AMLs 27.354
UPN44 PB Diagnosis 47 Dilution 50% OK NK-AMLs Test Set NK-AMLs 28.541
UPN73 PB Diagnosis 47 Dilution 50% OK NK-AMLs Test Set NK-AMLs 19.624
UPN97 BM Diagnosis 47 Dilution 50% OK NK-AMLs Test Set NK-AMLs 22.934
UPN1 PB Diagnosis 46 Dilution 50% OK NK-AMLs Test Set NK-AMLs 26.707
UPN66 BM Diagnosis 46 Dilution 50% OK NK-AMLs Test Set NK-AMLs 23.454
UPN78 PB Diagnosis 46 Dilution 50% OK NK-AMLs Test Set NK-AMLs 28.541
UPN25 BM Diagnosis 43 Dilution 50% OK NK-AMLs Test Set NK-AMLs 21.699
UPN38 BM Diagnosis 40 Dilution 50% OK NK-AMLs Test Set NK-AMLs 26.707
UPN74 BM Diagnosis 40 Dilution 50% OK NK-AMLs Test Set NK-AMLs 19.777
UPN89 BM Diagnosis 40 Dilution 50% OK NK-AMLs Test Set NK-AMLs 29.115
UPN19 BM Diagnosis 39 No Dilution OK NK-AMLs Test Set NK-AMLs 25.313
UPN11 BM Diagnosis 37 Dilution 50% OK NK-AMLs Test Set NK-AMLs 29.776
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malization (for the Training Set only). Briefly, the Invar-
iant Rank normalization method was applied to the
primary probe data obtained from the Training Set sam-
ples. Processed probe data were then filtered according
to the following criteria: minimal signal intensity fold
change of 1.50 across all samples; minimal probe signal
intensity absolute change of 150 across all samples
(choice based on the maximum expression levels of
XIST transcript in males, and CYorf15B transcript in
females); and maximal value for probe signal intensity of
50 000 across all samples. Among the 48 803 probes
assessed on HumanHT-12 v3 Expression BeadChips, 11
779 satisfied these low stringency filtering criteria. Fil-
tered data were then log-transformed and exported to
appropriate softwares for the analyses. Regarding the
Test Set samples processing, only data concerning the
markers identified during the first analysis, restricted to
the Training Set, were used. These raw data were log-
transformed and merged to the one of the Training Set
for class prediction analyses. The Class Prediction Mod-
ule of ArrayMiner 5.3.3 (Optimal Design, Brussels, Bel-
gium - http://www.optimaldesign.org), which uses a
proprietary method based on grouping genetic algo-
rithms, was used for all class prediction analyses (see
additional file 1 for details) [24]. This module allowed
calculating the confidence level of the class prediction
for each sample, or for a given group of samples, and
the fitness of the overall model. This estimator enabled
optimizing the number of probes/markers to be used
per class. Briefly, the confidence level of the class pre-
diction analysis reflected the strength with which the
probe/marker landed each sample into its predicted
class. More precisely, for each sample, the following
happened: (1) each probe/marker casted its vote for the
sample being in each of the train classes, (2) the votes
were summed up over all probes/markers, yielding a
vote for each of the classes, (3) the score of the winner
class (call it S1) was compared to the second best (call
it S2), and the confidence level of the classification of
the sample was computed as (S1-S2)/(S1+S2). In the
Cross-validation analysis, the same was performed,
except that the probe/marker set was recomputed each
time, leaving out the sample being tested in order to
yield an honest estimate of the worth of the method.
The fitness of a class prediction model was computed
on the test samples only, in order to estimate how good
the class prediction (of the “unclassified” samples) was,
and reflected the success with which the model was able
to correctly (re)classify the already “classified” samples.
The fitness of the model was in fact the result of a
cross-validation (as described above) on the Training
samples, with the integral part being equal to the num-
ber of correct (re)classifications, and the fractional part
being computed as follows: (1) if all samples were cor-
rectly classified, the average confidence level (as defined
above) of all samples, (2) if some samples were misclas-
sified, the average confidence level of the correctly clas-
sified samples minus the average confidence level of the
misclassified ones. If all samples were misclassified, the
fitness of the model was zero. Omics Explorer 2.2 soft-
ware (Qlucore, Lund, Sweden - http://www.qlucore.
com) was used for principal-component analyses. S-
Plus
® 8.0 Enterprise Developer software (Insightful Cor-
poration, Seattle, USA) was used for all other statistical
analyses. The two datasets (Training Set and Test Set)
discussed in this publication have been deposited in
NCBI’s Gene Expression Omnibus and are accessible
Table 3 Characteristics and class assignment of the 117 Test Set samples. (Continued)
UPN96 PB Diagnosis 35 No Dilution OK NK-AMLs Test Set NK-AMLs 27.303
UPN72 BM Diagnosis 25 Dilution 75% OK NK-AMLs Test Set NK-AMLs 26.707
UPN8 BM Diagnosis 24 Dilution 75% OK NK-AMLs Test Set NK-AMLs 27.357
UPN44 PB Diagnosis 24 Dilution 75% OK NK-AMLs Test Set NK-AMLs 29.235
UPN97 BM Diagnosis 24 Dilution 75% OK NK-AMLs Test Set NK-AMLs 24.035
UPN1 PB Diagnosis 23 Dilution 75% OK NK-AMLs Test Set NK-AMLs 26.707
UPN66 BM Diagnosis 23 Dilution 75% OK NK-AMLs Test Set NK-AMLs 19
UPN73 PB Diagnosis 23 Dilution 75% OK NK-AMLs Test Set NK-AMLs 24.104
UPN78 PB Diagnosis 23 Dilution 75% OK NK-AMLs Test Set NK-AMLs 28.541
UPN25 BM Diagnosis 21 Dilution 75% OK NK-AMLs Test Set NK-AMLs 18.99
UPN38 BM Diagnosis 20 Dilution 75% OK NK-AMLs Test Set NK-AMLs 25.107
UPN74 BM Diagnosis 20 Dilution 75% OK NK-AMLs Test Set NK-AMLs 19.705
UPN89 BM Diagnosis 20 Dilution 75% OK NK-AMLs Test Set NK-AMLs 26.555
UPN11 BM Diagnosis 19 Dilution 75% OK NK-AMLs Test Set NK-AMLs 24.587
UPN, unique patient number. BM, bone marrow. PB, peripheral blood. QCC, quality control criteria.
Low cRNA, amount of labeled cRNA hybridized on the BeadChip below 750 ng. Low RIN, RNA integrity number below 7.00.
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Page 6 of 12through GEO Series accession number GSE34823 http://
www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE34823.
The dataset associated with the Training Set is also
linked to the SubSeries accession number GSE34577.
The dataset associated with the Test Set is also linked
to the SubSeries accession number GSE34714.
Results
Identification of classifiers from optimal APL, t(8;21)-AML,
inv(16)-AML and NK-AML samples
First, using the Class Prediction Module of ArrayMiner
5.3.3 software, classifiers associated with the APL, t
(8;21)-AML, inv(16)-AML, NK-AML classes were
defined based on 71 samples containing at least 60% of
leukemic blasts and characterized by good quality con-
trol criteria (Optimal samples - Training Set). At this
stage, unique and pooled normal bone marrow samples
were also included in the model as the objective was to
enhance the predictive capacity of the classifiers, espe-
cially for Test Set samples containing a majority of resi-
dual normal cells and a low leukemic blast load.
Evaluating classifiers which included from 1 to 100 mar-
kers per class, all Training Set samples were assigned to
the correct class when selecting from 3 to 46 markers
per class (class prediction accuracy, sensitivity, specifi-
city, negative and positive predictive values, 100% for
each class - error rate, 0%), whether the source of leuke-
mic cells was bone marrow or peripheral blood. The
best model fitness was obtained with 8, 9 or 10 markers
per classifier. To select the optimal model among these
three, a principal-component analysis was performed.
The highest cumulative percent of variance accounted
for by the first three components was obtained with the
10-marker classifiers (cumulative percent of variance
with classifiers including 10 markers, 79 percent - addi-
tional file 1, Figure S1), which led to select these for
subsequent analyses (Figure 1). The best median confi-
dence levels for the correct assignment of the Training
Set samples were achieved with 10, 2, 1, and 9 markers
for APLs, t(8;21)-AMLs, inv(16)-AMLs, and NK-AMLs,
respectively (additional file 1, Figure S2). Regarding NK-
AMLs and in agreement with previous reports, the high-
est median confidence levels were observed for NK-
AMLs with mutated NPM1 and the lowest ones for NK-
AMLs with neither NPM1 nor FLT3 mutations (addi-
tional file 1, Figure S3) [22-26].
Class prediction analysis for suboptimal AML samples -
Impact of the leukemic blast load
Using the 10-marker classifiers, the GGA-based super-
vised method was subsequently applied to a series of
101 Test Set samples, with optimal quality control cri-
teria, for which the leukemic blast load was originally
below 60 percent or had been artificially lowered to less
than 60 percent blasts by dilution series. Only the classi-
fiers associated with one of the four AML classes were
Figure 1 Heatmap of the 40 markers used to define the four AML classifiers allowing the assignment of all Training Set AML samples
to the correct class. From the top to the bottom: APL, t(8;21)-AML, inv(16)-AML, and NK-AML classes - 10 markers per class (normal bone
marrow class is not represented). Each column represents a sample; each row represents a marker (gene transcript). The log2 relative gene
expression scale is depicted on the bottom left.
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Test Set samples were correctly classified, even when
containing as low as 2 percent blasts (Table 3 - Figure 2).
Twenty six of the 29 inv(16)-AML samples were
assigned to the expected class, including the 95 percent-
diluted ones which contained as low as 3 percent blasts
(error rate, 10 percent). In all three inv(16)-AML Test
Set samples that were incorrectly classified, CBFB-
MYH11 fusion gene was detected by FISH assay. For
APL, t(8;21)-AML and inv(16)-AML classes, the blast
load significantly influenced the confidence level of the
class assignment (Figures 3 - additional file 1, Figure
S4). For NK-AMLs, all but 1 of the 29 Test Set samples
were correctly classified (error rate, 3 percent) (Table 3).
This misclassified sample, obtained at diagnosis from
UPN60, had no NPM1, FLT3 or CEBPA mutations. Its
class assignment, characterized by a low confidence level
(given its blast load - Table 1, additional file 1, Figure
S4), was not confirmed as no PML/RARA fusion gene
was detected by FISH analysis and RT-PCR assay.
Across the range of leukemic blast loads studied in the
Test Set, the confidence level associated with the class
assignment of diluted AML samples was not different
from the one achieved for undiluted low leukemic blast
load samples (Table 3 - additional file 1, Figure S5). For
those 101 AML Test set samples with low leukemic
blast load and optimal quality control criteria, the over-
all error rate was 3.9 percent.
Class prediction analysis for suboptimal AML samples -
Impact of quality control criteria
When the performance of the 10-marker classifiers was
assessed on 10 samples that did not fulfill all quality
control criteria, all suboptimal samples were assigned to
the expected class, even though their leukemic blast
content was as low as 9 percent (median, 55 percent;
range 9 to 100 percent) (Table 3 - additional file 1, Fig-
ure S6). The confidence level for the class assignment of
these samples was not different from the one achieved
for the other Test Set samples (Data not shown).
Overall, the error rate was 3.6 percent for the entire
Test Set (excluding AML cell lines that were considered
as controls), and for each class, sensitivity and specifi-
city, negative and positive predictive values of the class
assignments ranged from 91 to 100 percent (additional
file 1, Figure S7).
Discussion
The integration of microarray-derived data to the cur-
rent workflow dealing with the prognostic evaluation of
AML patients requires the technology to deliver infor-
mative data for the majority of samples, including those
Figure 2 Results of the class assignment for the 107 AML Test Set samples fulfilling all quality control criteria based on the 10-marker
classifiers characterizing the APL, t(8;21)-AML, inv(16)-AML and NK-AML classes (all three AML cell lines run in duplicates included).
Each column represents a sample; each row represents a marker (gene transcript). The log2 relative gene expression scale is depicted on the
bottom left.
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focused on this kind of samples - either with a low leu-
kemic blast load, poor quality control criteria or both -
and the ability to identify favorable-risk karyotype AMLs
in such situations, using microarray-based GEP and a
class prediction method based on GGA. Apart from the
s t u d yo fd eR i d d e re ta l ,w h i c ha d d r e s s e dt h ei m p a c to f
random, fixed and group-specific impurities on the
results of differential gene expression analyses, using a
limited set of samples and computer simulations, the
influence of the leukemic blast load on class prediction
accuracy based on GEP data has never been specifically
studied so far [25]. To evaluate the capacity of microar-
ray-derived predictors to correctly assigned samples
with a low leukemic blast load, besides using “real”
AML samples with low blast percentage, i.e., less than
60 percent, a “dilution/mixture” approach was consid-
ered [26,27]. This strategy has already been successfully
applied to assess the efficiency of various normalization
methods applied to microarray datasets. It consisted in
diluting labeled cRNAs of originally high blast load
AML samples within pools of normal bone marrow
labeled cRNAs. This approach was also considered as in
some AML subtypes, such as t(8;21)-AMLs, more differ-
entiated cells (not counted as blasts) are frequently of
leukemic origin, leading to under-estimate the leukemic
load of some “low blast content” samples. Consequently,
it became possible to accurately control the percentage
of leukemic blasts within the Test Set sample down to 2
percent.
Overall, considering the 111 Test Set samples with
low leukemic blast load and/or suboptimal quality con-
trol criteria, whether being peripheral blood or bone
marrow samples, the predictive capacity of the GGA-
derived model with 10-marker classifiers was encoura-
ging, with specificities ranging from 0.98 to 1.00, and
sensitivities ranging from 0.91 to 1.00. Moreover, con-
sidering AML samples containing 20 to 56 percent
blasts, the overall error rate was lower than 1.4 percent
(1 misclassified NK-AML sample out of 72). Finally,
APL, t(8;21)-AML, and inv(16)-AML samples containing
as low as 2 percent blasts could be correctly classified,
whether the classifiers mainly relied on a single marker,
such as for inv(16)-AMLs and t(8;21)-AMLs, or on the
overall set of 10 markers defining the classifier, as for
APL samples. However, regarding APL, t(8;21)-AML
and inv(16)-AML samples, the confidence level of the
class assignment was correlated to the percentage of
leukemic blasts within the studied samples. For NK-
AML samples, such a finding was not observed, prob-
ably because NK-AMLs represent a more heterogeneous
group of leukemias as compared to t(8;21)-AMLs, inv
(16)-AMLs or APLs in term of oncogenic processes.
This heterogeneity likely led to a higher variance of
gene expression profiles within the NK-AML class, to
the detriment of the interclass variance, hence influen-
cing the class prediction confidence level more than the
leukemic blast load. This hypothesis was supported by
the fact that, within the NK-AML class, the best predic-
tive capacity of the GGA was achieved for NPM1-
mutated samples, in accordance with previous studies,
and the worst one for samples with no NPM1 and FLT3
mutations [28-31].
Unexpectedly, the worst results of the class prediction
analysis were achieved for inv(16)-AML Test set samples
(Sensitivity, 0.91; negative predictive value, 0.96). Among
the three misclassified inv(16)-AML samples and for
which the presence of CBFB/MYH11 fusion gene was
confirmed by FISH analysis, all contained less than 20
p e r c e n tb l a s t sa n dt w ow e r eo b t a i n e da tt h et i m eo f
relapse - from patients UPN7 and UPN37 -. Regarding
these two samples, which respectively contained 5 and
14 percent blasts, they were characterized by a low
expression level of most markers defining the inv(16)-
AML specific signature; especially MYH11,w h i c h
expression level was within the estimated background
signal range. It is noteworthy that for one of those two
patients, UPN37, the bone marrow sample obtained at
diagnosis was correctly classified, even when diluted at
50 and 75 percent (blast content, 20 and 10 percent,
Figure 3 Box plots of the confidence levels for the class
assignment of the APL, t(8;21)-AML, inv(16)-AML and NK-AML
Test Set samples according to their leukemic blast load. The
white vertical line and circle in the interior of the dark gray box is
located at the median of the data. The width of the box is equal to
the interquartile distance, which is the difference between the third
and first quartiles of the data. The interquartile distance indicates
the spread of the distribution for the data. The whiskers (the lines
extending from the left and right parts of the box) go to the
nearest value not beyond the span from the quartiles, i.e., 1.5 times
the interquartile distance from the center of the data. Points
beyond the whiskers are considered outliers and are drawn
individually, indicated in black (+).
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disease was suspected as CD2, CD13, CD34 and CD117
expression values, assessed by flow cytometry on gated
leukemic cells, and MYH11 expression level (microarray
data) were significantly lower in the relapse sample as
compare to the ones observed in the diagnostic sample.
Verhaak et al in their study using Affymetrix GeneChips
reported that MYH11 expression level was sufficient to
identify inv(16)-AMLs [10]. The present results suggest
that the use of MYH11 a st h es o l em a r k e rf o rt h ei n v
(16)-AML class could lead to unstable results in a class
prediction model, especially in low leukemic blast load
samples or in case of a clonal evolution at relapse. Of
note, the inv(16)-AML signature developed on the
AMLProfiler™ kit http://www.skyline-diagnostics.com,
which uses the Affymetrix™ platform, also includes a
set of 19 markers [32].
As reported by Kohlmann et al., sub-optimal AML
samples with poor quality control criteria, mainly
because of low amounts of hybridized cRNAs, were all
correctly classified, even though half of these contained
less than 60 percent blasts (down to 9 percent for
UPN90) [33]. Studying the impact of RNA degradation
on GEP analyses, similar results have been recently
reported by Opitz et al on a different microarray plat-
form [34]. As in the present study, they showed that
useful information could still be obtained from thermi-
cally degraded RNA; at least to a certain extent, and
depending on the length of the mRNA molecules. Inter-
estingly, even AML samples for which a third of the
required cRNA amount was hybridized on BeadChips
could be assigned to the correct class in the present
study, suggesting that the biological variance between
the AML classes was higher than the one related to
technical variability or artifacts. This result could also be
related to the fact that, during the sample processing,
the TotalPrep RNA Amplification kit that was used, did
not required any fragmentation step, which could
further alter poor quality RNA or lower the already
reduced cRNA amounts. These encouraging results, on
a limited set of poor quality samples, could also be
related to the classification method used, as the GGA-
based class prediction strategy aimed at finding the
most influential markers for each AML class (top mar-
kers with the highest inter-class variance and the lowest
intra-class variance). This GGA-based class prediction
method was indeed associated with the lowest error rate
and the highest predictive accuracy when compared to
other supervised methods, such as support vector
machines, random forests, artificial neural networks, k-
Nearest Neighbor or nearest shrunken centroids (also
known as PAM) (data not shown).
Although, in most cases, these favorable prognostic
chromosomal abnormalities and/or their related gene
products can be detected by karyotype, FISH or PCR
assay, they represent main targets for a microarray-
based class prediction analysis to be identified before
considering GEP as a useful tool in a routine workflow
for prognostic assessment of AML patients. The fact
that the AMLProfiler, a microarray-derived kit based on
the Affymetrix™ platform, has been recently commer-
cialized with the aim of achieving a molecular diagnosis
for APLs, t(8;21)-AMLs and inv(16)-AMLs, respectively
using 27, 31 and 19 markers, emphasizes this assump-
tion [32].
Finally, regarding the classifiers associated with APLs,
t(8;21)-AMLs or inv(16)-AMLs, 18 of the 28 markers
identified in this study (64 percent) had already been
reported in previous studies using various microarray
technologies (additional file 1, Table S1). These findings
(1) confirm that the Illumina bead-based technology is
as reliable, robust and sensitive as other microarray
technologies developed by commercial manufacturers or
academic facilities, and (2) suggest that the GGA-
derived class prediction approach is a highly efficient
one as it required a limited set of ten markers per class
to achieve accurate class assignments. Furthermore, this
study has identified new AML markers that will need
further studies to delineate their role in the leukemo-
genic events involved in APLs (CERCAM, COL23A1,
LOC643201, LOXL4, SLC39A11), t(8;21)-AMLs
(LOC440030, TNFRSF21), and inv(16)-AMLs (EFHC2,
GPR12, MEGF10).
Conclusions
In more than 96 percent of the suboptimal cases, using
a microarray-derived GEP approach and a GGA-based
class prediction method, favorable cytogenetic risk AML
samples with low leukemic blast load and/or poor qual-
ity control criteria could be correctly assign to the
appropriate class with a limited set of markers, allowing
to consider GEP as a useful tool in a routine workflow
for prognostic assessment of AML patients.
Additional material
Additional file 1: Sample preparation for gene expression profiling.
- Generation of biotinylated, amplified cRNA using The Illumina Total
Prep RNA Amplification Kit (Applied Biosystems/Ambion, Austin, USA). -
Generation of low leukemic blast load AML samples by a “dilution/
mixture” approach. - Hybridization on Illumina HumanHT-12 v3
Expression BeadChips, staining and detection of cRNAs on microarrays
using an I-Scan system. Additional table S1 - Citations in previous studies
of the identified markers. Additional figures S1 to S7. Figure S1. Three-
dimensional projection of the 3 principal components in a principal-
components analysis of APL, t(8;21)-AML, inv(16)-AML, NK-AML, and
Normal Bone Marrow samples belonging to the Training Set, with the
use of the 10-marker classifiers. Figure S2. Per class median confidence
level of the assignment for APL, t(8;21)-AML, inv(16)-AML, NK-AML and
normal bone marrow samples belonging to the Training Set according
to the number of markers per class (from 1 to 100 markers per class).
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Page 10 of 12Figure S3. Median confidence level of the class assignments for the NK-
AML samples belonging to the Training Set according to FLT3 and NPM1
mutational status and the number of markers per class (from 1 to 100
markers per class). Figure S4. Relationship between the percentage of
leukemic blasts within the 101 Test Set samples (X axis) and the
confidence level of their class assignments (Y axis) (samples with poor
quality control criteria and AML cell lines were excluded). Figure S5.
Confidence level of the class assignments according to the percentage
of leukemic blasts including comparisons between diluted and not
diluted samples. Figure S6. Results of the class assignment for the 10
AML Test Set samples with suboptimal quality control criteria based on
the 10-marker classifiers characterizing the APL, t(8;21)-AML, inv(16)-AML
and NK-AML classes. Figure S7. Sensitivity, specificity, negative and
positive predictive values of the prediction model for the class
assignment of the 111 Test Set samples (all AML samples with or
without optimal quality control criteria - AML cell line samples excluded)
to the APL, t(8;21)-AML, inv(16)-AML and NK-AML classes with 10-marker
classifiers.
List of abbreviations used
APL: acute promyelocytic leukemia; AML: acute myeloid leukemia; GEP: gene
expression profiling; GGA: grouping genetic algorithms; NK-AML:
cytogenetically normal acute myeloid leukemia; RIN: RNA integrity number.
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